Predictive Oncology Company Top Insiders
POAI Stock | USD 0.81 0.03 3.85% |
Under 85 percent of all Predictive Oncology's insiders are aggressively buying. The analysis of insiders' sentiment of trading Predictive Oncology stock suggests that a large number of insiders are very bullish at this time. Predictive Oncology employs about 34 people. The company is managed by 10 executives with a total tenure of roughly 80 years, averaging almost 8.0 years of service per executive, having 3.4 employees per reported executive.
Predictive Oncology's Insider Buying Vs Selling
85
Selling | Buying |
Latest Trades
2023-09-25 | Charles Lee Sr Nuzum Sr | Disposed 10000 @ 3.04 | View | ||
2022-12-15 | Daniel E Handley | Acquired 300 @ 8.2 | View | ||
2022-12-02 | Robert L Myers | Acquired 439 @ 11.4 | View | ||
2022-11-29 | Daniel E Handley | Acquired 500 @ 7.2 | View | ||
2022-05-26 | Daniel E Handley | Acquired 127 @ 7.4 | View | ||
2022-05-24 | J Melville Engle | Acquired 7975 @ 7.4 | View | ||
2022-05-20 | Robert L Myers | Acquired 806 @ 6 | View |
Monitoring Predictive Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Predictive |
Predictive Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.558) % which means that it has lost $0.558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4936) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.04. The current Return On Capital Employed is estimated to decrease to -1.4. As of now, Predictive Oncology's Non Currrent Assets Other are decreasing as compared to previous years. The Predictive Oncology's current Net Tangible Assets is estimated to increase to about 26 M, while Total Assets are projected to decrease to under 9.5 M.The Predictive Oncology's current Common Stock Shares Outstanding is estimated to increase to about 4.2 M, while Net Loss is projected to decrease to (24.3 M).
Predictive Oncology Workforce Comparison
Predictive Oncology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 14,928. Predictive Oncology adds roughly 34.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Predictive Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Predictive Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Chung-welch Nancy 2 days ago Acquisition by Chung-welch Nancy of 2675 shares of Predictive Oncology subject to Rule 16b-3 | ||
Hawryluk Matthew over three weeks ago Acquisition by Hawryluk Matthew of 18360 shares of Predictive Oncology subject to Rule 16b-3 | ||
Rao Veena over a month ago Insider Trading | ||
Handley Daniel E over two months ago Acquisition by Handley Daniel E of 4512 shares of Predictive Oncology subject to Rule 16b-3 | ||
Bush Pamela over three months ago Disposition of tradable shares by Bush Pamela of Predictive Oncology subject to Rule 16b-3 | ||
Chung-welch Nancy over six months ago Acquisition by Chung-welch Nancy of 2353 shares of Predictive Oncology subject to Rule 16b-3 | ||
Chung-welch Nancy over six months ago Acquisition by Chung-welch Nancy of 9924 shares of Predictive Oncology subject to Rule 16b-3 | ||
St Clair Gregory Sr over a year ago Acquisition by St Clair Gregory Sr of 1875 shares of Predictive Oncology subject to Rule 16b-3 |
Predictive Oncology Notable Stakeholders
A Predictive Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Predictive Oncology often face trade-offs trying to please all of them. Predictive Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Predictive Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MD FCAP | Senior Director | Profile | |
Joshua MBA | Interim Officer | Profile | |
BS BSc | VP RD | Profile | |
Pamela MBA | Chief Officer | Profile | |
Raymond Vennare | CEO Chairman | Profile | |
DSc OD | VP Operations | Profile | |
Julia Kirshner | Chief Officer | Profile | |
Robert Myers | CFO Sec | Profile | |
Robert MBA | CFO Sec | Profile | |
Theresa Ferguson | Director Marketing | Profile |
About Predictive Oncology Management Performance
The success or failure of an entity such as Predictive Oncology often depends on how effective the management is. Predictive Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Predictive management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Predictive management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.99) | (1.04) | |
Return On Capital Employed | (1.33) | (1.40) | |
Return On Assets | (0.97) | (1.02) | |
Return On Equity | (1.69) | (1.78) |
Predictive Oncology Workforce Analysis
Traditionally, organizations such as Predictive Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Predictive Oncology within its industry.Predictive Oncology Manpower Efficiency
Return on Predictive Oncology Manpower
Revenue Per Employee | 52.4K | |
Revenue Per Executive | 178K | |
Net Loss Per Employee | 411.3K | |
Net Loss Per Executive | 1.4M | |
Working Capital Per Employee | 180.2K | |
Working Capital Per Executive | 612.7K |
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |